Lumipulse® G Total Tau CSF
Immunoreaction cartridge for use with the LUMIPULSE G1200 for the quantitative measurement of total Tau in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
This product is For Research Use Only (RUO), not for use in diagnostic procedures.
Product # 231302
Product # 231326
Product # 231319
Powered by Bioz
-
Citations
The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.
-
Documentation
Browse regulatory documents for this product
Create a free membership account and start browsing all product documentation right away.
Get access to this section and more
Create a membership account to review and download product-specific documentation.
-
Insights
Jun 25, 2025Everything You Need to Know About Amyloid Presence and Alzheimer’s Disease-modifying Therapies
Confirming amyloid pathology before administering Alzheimer’s disease-modifying therapies.
Approximately seven million Americans are currently living...
May 20, 2025Video - The Scientist Symposium: Understanding Disease Through Biomarkers
The Evolution of AD Diagnosis: The Role of Biomarkers
Biomarkers are transforming the landscape of disease detection and diagnosis—especially in the...
May 8, 2025Modern Alzheimer’s Diagnosis: What Clinicians Need to Know About Biomarkers and Staging
What PET scans, CSF assays, and blood tests reveal about Alzheimer’s — and how the A/T/N framework supports earlier, more accurate diagnoses.
Alzheimer...
